Linn Woelber^*1, Sabrina Mathey^*1, Katharina Prieske^*†, Sascha Kuerti^*, Christoph Hillen^*, Eike Burandt^‡, Anja Coym^§, Volkmar Mueller^*, Barbara Schmalfeldt^*, Anna Jaeger^*

Oncology Research, Vol.28, No.6, pp. 645-659, 2020, DOI:10.3727/096504020X16076861118243

Abstract Therapeutic options in recurrent or metastasized vulvar squamous cell cancer (VSCC) not amenable to radiotherapy or radical surgery are limited. Evidence for the use of targeted therapies is sparse. All patients with VSCC treated at the Gynecological Cancer Center Hamburg-Eppendorf 2013–2019 were retrospectively evaluated for targeted therapeutic approaches. Furthermore, a MEDLINE, EMBASE, Web of Science, Scopus, and OVID database search was performed using the terms: “vulvar cancer” AND “targeted therapy,” “erlotinib,” “EGFR,” “bevacizumab,” “VEGF,” “pembrolizumab,” or “immunotherapy.” Twelve of 291 patients (4.1%) with VSCC received at least one targeted therapy at our institution. Previously, one or more platinumbased chemotherapy was… More >

T. Pudlarz, N. Naoun, G. Beinse, D. Grazziotin-Soares, J.-P. Lot

Oncologie, Vol.21, No.1, pp. 53-68, 2019, DOI:10.3166/onco-2019-0036

Abstract In this special issue of Oncology, we have summarized the most relevant topics that were presented at the American Association for Cancer Research (AACR) meeting. Our purpose here is to give the readers a concise report of the presentations that warrant particular attention. This year 2019 in Atlanta, the AACR Annual Meeting program covered the latest discoveries across the spectrum of cancer research — from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy — and highlights the work of the best minds in research and medicine from institutions all over the world. It… More >